Therefore, dual inhibitors targeting host CTSL and CAPN1 might bring broad-spectrum synergistic efficacy to the fight against coronavirus in the future, while reducing excess inflammation to improve symptoms in patients with viral infections. The gene discussed is CAPN1; the disease is viral infectious disease.